The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|November 15, 2022
People and Business News — 11/22
Advertisement
People News
physIQ announced Jason Luke has been appointed to the company’s Medical Advisory Board.
Canary Medical announced the appointment of Lisa Suennen as President, Digital and Data Solutions.
Business News
Emmes has expanded capabilities in India during the last two years and has seen surging growth in the region, with local revenue increasing by 400% and global study revenue increasing by more than 50%.
ACTO has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence by Everest Group.
eClinical Solutions announced its accreditation in Medidata’s Site Cloud: End of Study platform.
The Almac Group has pledged to be net zero by 2045.
Quanticate announced plans for further expansion and new jobs in Toronto in 2023 as it thrives post-pandemic after it opened the office in 2019.
physIQ announced that OncoBay Clinical, Inc., has joined its Intrepid Partner Program.
Recognition
Elligo Health Research just won the Fast 50 Award, sponsored by the Austin Business Journal.
Jumo Health announced it has been recognized by Inc. Magazine in its inaugural Power Partner Awards.
AeroSafe Global announced that it earned the No. 1 spot on the 2022 Top 100 list of fast-growing, privately owned companies in the Rochester and Finger Lakes region.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5